GlassScriptPhysician profile
Gregory D Ferguson
NPI 1588205660
$5,090.77
in general payments reported to CMS, 2019-2025
25 companies · $44.06 in 2025
The $44.06 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,276 · 2022: $1,191 · 2023: $1,234 · 2024: $1,346 · 2025: $44.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $17.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.57 |
| Education | $17.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $890.10 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $685.01 | 2021-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $471.83 | 2021-2024 | Dupixent |
| Kaleo, INC. | $434.89 | 2021-2024 | Auvi-Q |
| Genzyme Corporation | $372.11 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $364.46 | 2021-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $270.23 | 2021-2024 | Takhzyro, Cuvitru |
| Blueprint Medicines Corporation | $255.33 | 2023-2024 | Ayvakit |
| Octapharma USA, INC. | $251.48 | 2024 | Cutaquig |
| Optinose US, INC. | $215.89 | 2021-2024 | |
| Genentech USA, INC. | $148.89 | 2021-2024 | Xolair |
| Amgen INC. | $148.26 | 2021-2024 | Tezspire |
| Pfizer INC. | $125.29 | 2021 | |
| Hikma Pharmaceuticals USA | $79.11 | 2022-2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $70.30 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $60.51 | 2023 | Xembify |
| Csl Behring | $47.18 | 2021-2024 | Haegarda |
| Incyte Corporation | $33.90 | 2022-2024 | Opzelura |
| Adma Biomanufacturing LLC | $30.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.03 | 2022 | |
| Alk-Abello, INC | $25.95 | 2021 | |
| Phadia US INC. | $24.98 | 2024 | Immunocap |
| Pharming Healthcare, INC. | $22.31 | 2025 | Ruconest |
| Ucb, INC. | $21.75 | 2025 | |
| Philips North America LLC | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.